Oxford Science Enterprises, an independent investor specializing in building companies through its relationship with the U.K.’s University of Oxford, has raised a further £250 million (US$300 million) to translate academic research into commercial products and businesses.
Even without an oracle, it is clear that Delfi Diagnostics Inc.’s $225 million series B fundraising round positions the company well to further develop its liquid biopsy tests for early cancer detection and monitoring. Delfi’s liquid biopsy platform uses a whole genome fragmentation analysis approach for both individual cancer and multicancer detection.
Qiming Venture Partners has closed funds worth a total $3.2 billion for health care-related investments, with funds spread across the five areas of biopharmaceuticals, med tech, diagnostics, health care services and IT.
Oxford Science Enterprises, an independent investor specializing in building companies through its relationship with the U.K.’s University of Oxford, has raised a further £250 million (US$300 million) to translate academic research into commercial products and businesses.
Precision Autoimmune Therapeutics Co. Ltd. has raised ¥140 million (US$21 million) in its first financing round to speed up its pipeline development and improve its drug development platform. Emerging Technology Partners LLC, Redhill Capital and CASI Pharmaceuticals Inc. participated in the round.
Med-tech financings in the second quarter of 2022 rose from last quarter by 26% with a total $8.5 billion raised, the most for a Q2 in all years prior to 2020.
RSS
